Assessing the risk of T-cell malignancies in mouse models of scid-x1

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 868-870

  Sorrentino, Brian ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER RISK; CD34 SELECTION; CELL TRANSPLANTATION; CHROMOSOME TRANSLOCATION; CHRONIC GRANULOMATOUS DISEASE; GENE EXPRESSION REGULATION; GENE MUTATION; GENOTOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT TRANSFORMATION; MURINE LEUKEMIA VIRUS; MYELODYSPLASTIC SYNDROME; NONHUMAN; NOTE; PROMOTER REGION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STEM CELL GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; GENE THERAPY; GENETIC VECTORS; LENTIVIRUS; MICE; MICE, SCID; T-LYMPHOCYTES;

EID: 77952004122     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.69     Document Type: Note

References (31)

1. Buckley, RH (2004). Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 22:625-655.
2. Hacein-Bey-Abina, S, Le Deist, F, Carlier, F, Bouneaud, C, Hue, C, De Villartay, JP et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185-1193. (Pubitemid 34984579)
3. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [see comments]. Science 288:669-672.
4. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364:2181-2187.
5. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360:447-458.
6. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, Mc-Cormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419.
7. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256.
8. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118:3143-3150.
9. McCormack, MP and Rabbitts, TH (2004). Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 350:913-922.
10. Nienhuis, AW, Dunbar, CE and Sorrentino BP (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13:1031-1049.
11. Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biasco, L, Recchia, A et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117:2233-2240.
12. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16:198-204.
13. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401-409.
14. Modlich, U, Schambach, A, Brugman, MH, Wicke, DC, Knoess, S, Li, Z et al. (2008). Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 22:1519-1528.
15. Calmels, B, Ferguson, C, Laukkanen, MO, Adler, R, Faulhaber, M, Kim, HJ et al. (2005). Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106:2530-2533.
16. Metais, JY and Dunbar, CE (2008). The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther 16:439-449.
17. Ginn, SL, Liao, S H Y, Dane, AP, Hu, M, Hyman, J, Finnie, JW et al. (2010). Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and γc overexpression. Mol Ther 18:965-976.
18. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16:718-725.
19. Shou, Y, Ma, Z, Lu, T and Sorrentino, BP (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103:11730-11735.
20. Scobie, L, Hector, RD, Grant, L, Bell, M, Nielsen, AA, Meikle, S et al. (2009). A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Mol Ther 17:1031-1038.
21. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knöss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108:2545-2553.
22. Ryu, BY, Evans-Galea, MV, Gray, JT, Bodine, DM, Persons, DA and Nienhuis AW (2008). An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111:1866-1875.
23. Will, E, Bailey, J, Schuesler, T, Modlich, U, Balcik, B, Burzynski, B et al. (2007). Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol Ther 15:782-791.
24. Persons, DA (2010). Lentiviral vector gene therapy: effective and safe? (2010). Mol Ther 18:861-862.
25. Li, CL and Emery, DW (2008). The cHS4 chromatin insulator reduces gammaretroviral vector silencing by epigenetic modifications of integrated provirus. Gene Ther 15:49-53.
26. Arumugam, PI, Scholes, J, Perelman, N, Xia, P, Yee, JK, Malik, P (2007). Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther 15:1863-1871.
27. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119:964-975.
28. Deichmann, A, Hacein-Bey-Abina, S, Schmidt, M, Garrigue, A, Brugman, MH, Hu, J et al. (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117:2225-2232.
29. Mullighan, CG, Miller, CB, Radtke, I, Phillips, LA, Dalton, J, Ma, J et al. (2008). BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114.
30. Ferrando, AA, Neuberg, DS, Staunton, J, Loh, ML, Huard, C, Raimondi, SC et al. (2002). Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1:75-87.
31. Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Gene therapy: therapeutic gene causing lymphoma. Nature 440:1123.